AI-based CT assessment of sarcopenia in borderline resectable pancreatic Cancer: A narrative review of clinical and technical perspectives.

BACKGROUND

Sarcopenia, defined as the progressive loss of skeletal muscle mass and function, has been associated with poor prognosis in patients with pancreatic cancer, particularly those with borderline resectable pancreatic cancer (BRPC). Although body composition can be extracted from routine CT imaging, sarcopenia assessment remains underused in clinical practice. Recent advances in artificial intelligence (AI) offer the potential to automate and standardize this process, but their clinical translation remains limited. This narrative review aims to critically evaluate (1) the clinical impact of CT-defined sarcopenia in BRPC, and (2) the performance and maturity of AI-based methods for automated muscle and fat segmentation on CT images.

METHODS

A dual-axis literature search was conducted to identify clinical studies assessing the prognostic role of sarcopenia in BRPC, and technical studies developing AI-based segmentation models for body composition analysis. Structured data extraction was applied to 13 clinical and 71 technical studies. A PRISMA-inspired flow diagram was included to ensure methodological transparency.

RESULTS

Sarcopenia was consistently associated with worse survival and treatment tolerance in BRPC, yet clinical definitions and cut-offs varied widely. AI models-mostly 2D U-Nets trained on L3-level CT slices-achieved high segmentation accuracy (mean DSC >0.93), but external validation and standardization were often lacking.

CONCLUSION

CT-based AI assessment of sarcopenia holds promise for improving patient stratification in BRPC. However, its clinical adoption will require standardization, integration into decision-support frameworks, and prospective validation across diverse populations.